GOSS Stock Overview
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Gossamer Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.67 |
| 52 Week High | US$1.88 |
| 52 Week Low | US$0.45 |
| Beta | 1.74 |
| 1 Month Change | -45.53% |
| 3 Month Change | -16.26% |
| 1 Year Change | -46.83% |
| 3 Year Change | -92.30% |
| 5 Year Change | -95.93% |
| Change since IPO | -96.27% |
Recent News & Updates
Recent updates
Peaking Back In On Gossamer Bio
Sep 27Gossamer Bio to raise $120M in a private equity placement
Jul 13Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
Jun 25
Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Jan 19Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?
Sep 22Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares
Jan 28Gossamer Bio (GOSS) Investor Presentation - Slideshow
Nov 18Shareholder Returns
| GOSS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.9% | 1.0% | 1.2% |
| 1Y | -46.8% | 0.7% | 24.9% |
Return vs Industry: GOSS underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: GOSS underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| GOSS volatility | |
|---|---|
| GOSS Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GOSS's share price has been volatile over the past 3 months.
Volatility Over Time: GOSS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 135 | Faheem Hasnain | www.gossamerbio.com |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
Gossamer Bio, Inc. Fundamentals Summary
| GOSS fundamental statistics | |
|---|---|
| Market cap | US$151.14m |
| Earnings (TTM) | -US$179.82m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs GOSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOSS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$179.82m |
| Earnings | -US$179.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 333.0% |
How did GOSS perform over the long term?
See historical performance and comparison